Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Leukemia, Myeloid, Acute 5Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Immunoblastic Lymphadenopathy 2Hematologic Diseases 2Burkitt Lymphoma 2Breast Neoplasms 2Sarcoma, Synovial 1Recurrence 1Neuroblastoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1

Interventions

Cyclophosphamide 13Etoposide 10Prednisone 8Doxorubicin 8Whole-Body Irradiation 7Vincristine 7Rituximab 7Peripheral Blood Stem Cell Transplantation 7Melphalan 7Brentuximab Vedotin 7romidepsin 6fludarabine phosphate 6Mycophenolic Acid 6fludarabine 5Lenalidomide 5Gemcitabine 5Cytarabine 510-propargyl-10-deazaaminopterin 5Tacrolimus 4Granulocyte Colony-Stimulating Factor 4Carmustine 4Busulfan 4Antilymphocyte Serum 4pembrolizumab 3etoposide phosphate 3carmustine, poliferprosan 20 drug combination 3Vorinostat 3Sirolimus 3Nivolumab 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, T-Cell × Leukapheresis × Clear all
NCT01746173 2023-01-30

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Terminated
5 enrolled 7 charts
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡